The writer is a long term value investor and M.Sc graduate in Financial Markets with over 10 years experience. Value can be found in both long and short ideas and uses options to enhance the risk-return profile of investment ideas.
Disclaimer: This article provides opinions and information, but does not contain recommendations or personal investment advice to any specific person for any particular purpose. Do your own research or obtain suitable personal advice.
Every stock has a story, and that story is told each day the stock market opens.
Market DJ: Research, Enlightenment, Entertainment
Listening to the market, cutting through the noise... Finding good products & companies, crunching numbers... Looking for long-term macro trends in consumer spending habits... Learning through research and market performance...
Focusing on US Listed Companies:
–retail and technology trends
–media and entertainment products
–food & beverage, restaurant, and hospitality
–long & short opportunities
We conduct independent, boots on the ground research, as well as the numbers. Go with what you know. Every stock has a story, and that story is told each and every day in the stock market. We look at the product, the company, then the numbers. I am djkidm, and teamed with knowledgable family & friends form Market DJ– research with a goal of making money & sharing that research publicly every once in a while to measure performance & receive criticism & advice.
Market DJ is mainly interested in growth & value. Companies that make money, preferably American, but we invest around the world. We look for at least 10% or more growth per year, and want a good product, company, and market, no excuses.
Range Bound or Down?
As of late 2015, we have turned bearish, at least in the cyclical sense. We shall see. In January of 2016 Market DJ formed Portfolio Lab: $100,000 of real cash with the goal of making money in a Bear Market, or Side Bear, which ever the case. Portfolio Lab serves a trading account with nimbleness being the golden rule. More details via articles or instablogs will be forthcoming depending upon time constraints. So far we have made very few moves; currently Long F, Long APPL, Long TWTR, Long GLD, Long SLV, Long JO (Coffee Futures), Short NFLX, short UAA, short CMG, and sitting with 72% cash....
waiting to strike...
I have a background in Journalism, and I hope to shed some light upon the media practices I witness each day in the Stock Market. I graduated from Portland State University in 2003 with a BA in English. I make money as a restauranteur, deejay, and writer. I joined the market in June of 2013, which presented some terrific buying opportunities. Recently I quit my night job as a bartender to concentrate on business plans, market research, and to continue making money in the market. So far so good :)
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
MD, MBA (Finance, NYU-Stern), certificate in financial modeling (Wharton). *Tipranks profile not accurate as doesn't pick up my premium ratings. Founder: Vasuda Healthcare Analytics (premium U.S. Biotech/pharma research) and Trident Asian Research (premium Asian investments research, www.tridentasia.com)
- Investment insights contributor: SumZero, Buy-side Institutional Platform (sumzero.com). Members of the platform include some of the largest hedge funds and asset managers.
-Former Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform (was ranked among top 10 out of over 100 contributors). Clients included some of the largest hedge funds and asset managers.
- Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
- Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
- Founder, managing principal of Vasuda Capital Management, healthcare-focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts.
- Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Just another guy with a day job and an obsession with the stock market... my goal is to achieve FI (financial independence) sooner rather than later.
My biggest successes have been in the biotech arena (over $300k personal portfolio profits), while my biggest losses have been due to overconfidence and a failure to adequately heed the bear thesis on my picks.
Most of the companies I investigate are growth or turnaround stories.
Important Note for Readers: I'm incredibly thankful for how my investing journey has turned out since first starting in 2008. Although I feel like I'm starting from square one all over again, my past wins have allowed me to buy my penthouse here in Peru, as well as start a clothing chain (with my wife) that I have hopes for. I don't have positions in most of the stocks I write about due to buying the apartment and starting the business. However, at a future time when more funds are available I look forward to having more skin in the game again. In the meantime, I write about stocks as I would approach them, my thesis and game plan- hoping that others find it useful.
I have been an Analyst on both the Buyside and Sellside. In addition, I have worked in a Corporate Strategy and Finance role for technology services companies. For many years I've been building quantitative models to create risk-adjusted, return-driven products for DIY individual investors through our platform Graycell Advisors. Our biotech related product - The Prudent Biotech Portfolio - is a quantitative-driven systematic investing product.
For the year 2016, the Prudent Biotech Portfolio was up +7%, compared to IBB (representing Nasdaq Biotech Index) decline of -21%. In addition, the Graycell Smallcap Portfolio was up +71% compared to benchmark Russell 2000 Index gain of +19%.
We invite you to take a look at the Graycell Advisors and Prudent Biotech websites for Performance, Philosophy, and Approach, and decide for yourself if the Biotech and Small Cap products can contribute to your investment objectives.
You can even view Samples, Register for a Free Pick from the Portfolio, and also check the Risk-free Subscription with a 60-day Money-back Guarantee.
Nothing here or on the site constitutes a personalized investment recommendation, and stocks mentioned in the reports/articles/comments may be now or in the past, part of the portfolios recommended by Graycell Advisors and related entities. Graycell Advisors and related entities are not a Registered Investment Advisor (RIA).
Any questions, please write to Support @ PrudentBiotech.com
I'm a tech professional who seeks out stocks with asymmetric risk/reward profiles, primarily in the biotech and tech sectors. I often take medium-term positions in risky contrarian markets with the expectation of large time-averaged gains from these special situations. I'm always looking for an undervalued opportunity, even if it's long term, regardless of market cap. I also follow and comment on commodities and demographics.
At Integer Investments we focus on US and European equities with a value/GARP strategy. Most articles are written by our portfolio manager Cristiano Bellavitis, Ph.D.
Cristiano is also an Assistant Professor at the Auckland Business School (New Zealand). He earned a Ph.D. from Cass Business School, City University of London. He applies academic rigour to our investment strategy.
If you want us to follow certain stocks or if you are interested to learn more about Integer Investments feel free to get in touch.
I am a 40 year old investor with a long term perspective and a lot of patience. I mainly think about the future when investing in stocks. I do not care about what my selection of stocks will do next year, but what the result will be in 2040 or so. To paraphrase Warren Buffett: "You should only have stocks that you would feel comfortable having if the stock market closes up for 10 years." That means that I look for stocks that combine growth and value. It has been proven that the group of dividend initiators and fastest dividend growers outperforms the markets by far in the long run. So I mainly select stocks from this group, although I also select some non-dividend payers that I believe will grow out to great future value players. Hence: from Growth to Value. I appreciate your comments, because I believe I can learn a lot from your feedback and I believe in the wisdom of crowds.
I'm the author of six published books, an investor, and a cancer survivor. I got my start thirty-two years ago ghost-writing for a UCLA econ. prof who owned a popular stock-picking newsletter. I have been extensively involved in clinical research (consulted with various medical colleges on new technologies) as well as a speaker in post-doctoral continuing ed in the US, UK, and Canada. Right now, I'm re-editing books for publication and writing articles on Seeking Alpha for others who (like me) enjoy doing extensive investment research and profiting from it.
We are a team of scientists at the Johns Hopkins University School of Medicine combining our expertise in biomedical research to identify undervalued assets within the biotechnology sector, as well as our background in quantitative and data science to generate statistical models for steady income generation.
I am the son of an Army pilot, a former chef and long time trader/market watcher. I currently write analysis and commentary for OptionInvestor.com where you can find me on Monday's and Thursdays, when I write the daily Market Wrap. OptionInvestor.com is a package of newsletters focused on using options to improve returns and increase income.
I take a fundamental approach to technical trading where I keep abreast of economic events while applying them to the charts. My main focus is the SP 500 but I am not limited to that. I currently trade gold, oil, the dollar as well as the indices and stocks.
I have taken a profound interest into demographics and how they are affecting market dynamics. My articles here on SeekingAlpha are the result of years of economy watching and research inspired by such.
I am professional with many years of experience in the pharmaceutical, biotech and device industry covering all functional areas from R&D to product commercialization. I write on Seeking Alpha regarding topics that I find interesting and focus on in depth financial and scientific research.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I invest in companies that have stock prices much lower than my analysis of their long term earnings potential suggest is warranted. I look mostly at a 3-5 year time horizon, but when I feel a case is extremely compelling over a 1-2 year time frame I sometimes add long dated options positions to my core holdings of common stocks. With a few stocks I own, I've continuously liked the 3-5 year horizon over a long period, and thus have several positions that date back to 1998.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
Education: BA Economics
Experience: I am a lawyer by trade, but have been studying economics and public companies for more than 20 years. I manage family retirement funds.
Disclosure: My articles and comments are solely my opinion, not an investment recommendation or solicitation, and may not represent the views of my employer(s), associates, or other related parties. No guarantees made to accuracy or completeness. I may be long or short in the companies mentioned, and may change my position at any time for any reason. Please do your own due diligence before making any investment. My opinions on Seeking Alpha contain information from numerous sources including, but not limited, to financial statements and other data. This data may not be correct. I advise you to double check the data and information before making any decision on purchasing or selling shares of the equities mentioned. I make no guarantees or warranties as to the accuracy of data or information used in my opinions.
Investment analyst and private investor. Began as trader and short-seller but changed my style few years ago and so I'm lifetime optimist now (as well as one of my idols André Kostolany) - I’m long only. I only write about stocks that I also own. Everything I write is only my opinion and of course, I could be wrong. Always do your DD. I’m stock picker looking for off-the-radar small or nano-cap mostly with a potential to growth hundreds of percent. I prefer stocks from biotech or alternative energy sector, but this is not a dogma. All my investments are long term, risky and I know that I could lose whole or big part of my initial investment....you should also count with it
I provide stock and bond analysis to a small cap specialist investor. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com. I still enjoy IT consulting and always have some sort of R&D project going on.
Full Time Micro Cap Investor. Founder of MicroCapClub.com
Founded in 2011, MicroCapClub is an exclusive forum for experienced microcap investors focused on microcap companies (sub $300m market cap). MicroCapClub was created to be a platform for experienced microcap investors to share and discuss stock ideas. MicroCapClub’s mission is to foster the highest quality microcap investor Community, produce Educational content for investors, and promote better Leadership in the microcap arena.
Disclosure: I'm not a financial adviser. All articles are my opinion - they are not suggestions to buy or sell any securities. Perform your own due diligence and consult a financial professional before trading.
Sirius capital is a Life Science consultancy firm providing guidance to investors and entrepreneurs in private and publicly traded companies. The managers are Mr. Dror Ozeri, CPA. Adv. and Dr. Ariel Kamsler PhD who combine their extensive experience in Pharma and drug development with financial management expertise.
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012.
ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.
Visit: ChinaBio Today (http://www.chinabiotoday.com)
ChinaBio LLC (http://www.chinabiollc.com)
Hello, my name is Bernardo Teixeira and welcome to my page! I'm currently an undergraduate student of Northeatern University majoring in Finance and Computer Science. My investment focus is majorly in value plays, and sometimes in portfolio strategy and macro trends. Since I'm originally from Brazil and I have lived in China for a few years I have a special passion for emerging market equities and investments outside of the United States. I'm currently following three industries; insurance, semiconductors, and airlines. As always please let me know if you have any comments about my articles!
In order to value a company we usually apply three different types of valuation:
1. Comparable Valuation: If we identify a company has enough comparable companies (usually around 4) and their corporate structures are similar to each other than we would likely value this company through a comparable valuation. In our opinion a comps val is not conclusive enough to know whether a company is being mis-priced by the market, but it provides enough information as to understand which stock of the bunch is the cheapest. Below is one good example of a comparable company and one bad one.
A very good example of a stock which we would rely on a comps val is Delta (DAL). Delta is in an industry which there is little product differentiation and airlines have similar corporate structures. In contrast Microsoft (MSFT) is a company which I probably would not use a comps val, because there is no other company that sells the same exact product line as MSFT.
In our comps valuation we use two different sets of ratios. Equity multiples such as P/E, P/S, P/B and PEG, and Enterprise multiples such as EV/Sales, EV/EBITDA, EV/FCF and EV/ Gross Cash Flow. We try to have all our ratios in a forward looking manner using average analyst expectations whenever possible. We also might eventually exclude ratios from the calculation that are not conclusive enough or that have a high dispersion among players of the industry.
2. Discounted Cash Flow Valuation: After completing our comps val my next step is to run a DCF valuation of the company. Usually our preference for a DCF is to not effectively predict what is going to happen in the future, but instead identify how the market is pricing the stock and stipulate three scenarios assumptions. These scenarios are used to estimate what are different analyst expecting from this company and whether those expectations are realistic or not. The bull case scenario reflects the highest analyst expectation, the base case the average, and the bear case the lowest. We also adjust margins accordingly as to reflect the opinion of analyst. For stocks that have a wide coverage this usually a good measure of the market's view of the company. In general we are only long companies that have a very attractive risk/reward ratio, in which the bull case fairly outstrip the base and the bear case is not significantly negative.
Another assumption we like to make is concerning the discount rates. In our opinion relying on CAPM to calculate the expected rate of returns is a very poor choice. There are many problems with CAPM that are not worth mentioning here. Instead we believe that using a base 8% discount rate subjectively adjusted by it the riskiness of the stock is a better approximation of the discount rate.
3. Return on Invested Capital Valuation: Another type of valuation that we like to use is the ROIC method. I'm still developing a model that can be successfully deployed for Seeking Alpha articles. Once I have it complete I will update our assumptions on our methodology.
Companies that we follow: Ping An (PNGAY), PICC (PPCCY), Copa Holdings (CPA), Cameco (CCJ), Qualcomm (QCOM), Noble Energy (NBL), Delta (DAL), Arotech (ARTX).
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
David Dierking is an analyst and writer focusing primarily on ETFs, mutual funds, dividend income strategies and retirement planning. He is a current contributor for Seeking Alpha, ETF Daily News, MutualFunds.com and ETFdb.com. He was also included in the panel for ETFReference.com’s “101 ETF Investing Tips from the Experts”.
If you're interested in learning more about dividend income strategies, retirement and ETF analysis, please consider following me by clicking on the "Follow" button at the top of this page next to my name.
In addition, you can find me on:
Twitter - @david_dierking
LinkedIn - David Dierking
Website - ETF Focus
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution. My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector. I am a contributing writer at CNA Finance and cover emerging opportunities as well as breaking news events.
I am Chirag Shah. I have a Masters degree in Pharmacy. Pharma and Biotech are my passion. I am an opportunistic investor. Currently I am working with a growing generic drug development company as a pharmaceutical formulation scientist.